MMR-D/MSI-H Colorectal CancersPhase 2NCT06365970
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
A Phase 2 study testing Niraparib and Dostarlimab in people with MMR-D/MSI-H Colorectal Cancers, run by Ibrahim Halil Sahin.
Trial summary
The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MMR-D/MSI-H Colorectal Cancers
- What is being tested?
- Niraparib and Dostarlimab
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 31 Jan 2025to Jan 2028
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed mismatch repair deficient or microsatellite instability high advanced stage colorectal cancer
- Measurable disease per RECIST v1.1
- ECOG 0 to 2
- Age ≥ 18 years
- Able to swallow oral medication (tablets).
- Progression on prior anti-PD1 ± anti-CTLA4 therapy.
Show all 20Show fewer
- Adequate organ function based on the following lab assessments:
- ANC must be ≥ 1500/mm3.
- Platelet count must be ≥ 100,000/mm3.
- WBC count ≥ 2.5 × 109 /L
- Hemoglobin must be ≥ 9 g/dL.
- Alkaline phosphatase ≤ 2.5× upper limit of normal (ULN) with the exception of patients with documented liver or bone metastases who should have ALP ≤ 5.0× ULN.
- AST and ALT≤ 2.5× ULN with the exception of patients with documented liver metastases who may have AST and/or ALT ≤ 5.0× ULN.
- International normalized ratio (INR) ≤ 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless receiving treatment with therapeutic anticoagulation.
- Total bilirubin ≤ 1.5× ULN (≤3× ULN if Gilbert syndrome present)
- Serum albumin ≥ 2.8 g/dL or 28 g/L
- Creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault equation.
- Patient who experienced progression of disease on prior anti-PD1 ± Anti-CTLA in the adjuvant and neoadjuvant settings are eligible to be enrolled in this trial without requirement of a second line of immunotherapy for advanced stage disease.
- Women of childbearing potentials must use a contraceptive method that is highly effective (with a failure rate of <1% per year), from the screening visit through at least 120 days after the last dose of study treatment and agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.
- Men must agree to use adequate contraception for the duration of trial participation and for 4 months after the last dose of study drugs. Men must also agree to not donate sperm. Men must agree to use adequate contraception for the duration of trial participation and for 4 months after the last dose of study drugs. Men must also agree to not donate sperm.
Who cannot join
- More than 2 lines of systemic therapy (excluding adjuvant therapy)
- Prior oxaliplatin based chemotherapy for metastatic disease. This excludes adjuvant oxaliplatin. Patients who received oxaliplatin based chemotherapy for metastatic disease before determination of MMR-D/MSI-H status (due to test turn-around time) can be enrolled if they received 4 or less cycle of oxaliplatin treatment (each cycle is one dose).
- More than 1 line of anti-PD1 based therapy.
- History of severe hypersensitivity to anti-PD1 monoclonal antibodies
- Prior PARPi
- Progression on platinum-based chemotherapy
Show all 36Show fewer
- Active autoimmune disease requiring immune suppression except following conditions:
- Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone without an active complication are eligible for the study.
- Patients with well controlled Type 1 diabetes mellitus who are actively on an insulin regimen are eligible for the study.
- Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- Disease is well controlled at baseline and requires only topical corticosteroids. - No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months.
- Active untreated brain metastasis (patients treated brain metastasis within 4 weeks can be enrolled)
- Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
- Received colony-stimulating factors (e.g., granulocyte macrophage colony-stimulating factor or recombinant erythropoietin) within 4 weeks.
- Previously or are currently participating in a treatment study of an investigational agent within 4 weeks of the first dose of therapy preceding the study.
- Received live vaccine within 30 days of planned start of study randomization. Study patients can be vaccinated against Corona virus disease 2019 (COVID-19) using vaccines authorized via the appropriate regulatory mechanisms. Note: messenger ribonucleic acid (mRNA) and adenoviral-based COVID-19 vaccines are considered nonlive. If COVID-19 vaccine is administered at any time, the date, name of the COVID-19 vaccine anatomic location, must be entered in the eCRF.
- Hypersensitivity to the components of niraparib or the formulation excipients.
- Undergone major surgery within 4 weeks of starting the first dose of study treatment or have not recovered from any effects of any major surgery.
- Have a second primary malignancy. Exceptions are the following:
- Adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, Stage I Grade 1 endometrial carcinoma
- Other solid tumors and lymphomas (without bone marrow involvement) diagnosed ≥5 years prior to randomization and treated with no evidence of disease recurrence and for whom no more than 1 line of chemotherapy was applied.
- Current active pneumonitis or any history of pneumonitis requiring steroids (any dose) or immunomodulatory treatment within 90 days of planned start of the study.
- Any clinically significant concomitant disease or condition (such as transfusion-dependent anemia or thrombocytopenia) that could interfere with, or for which the treatment might interfere with, the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patients in this study.
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study requirements and/or follow-up procedures. Those conditions should be discussed with the patients before study entry.
- High medical risk due to a serious, uncontrolled medical disorder; nonmalignant systemic disease; or active, uncontrolled infection (including COVID-19). Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, active uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits obtaining informed consent.
- Uncontrolled hypertension defined as SBP>180 and DBP>100 should receive antihypertensive medical therapy for blood pressure control (to achieve SBP<160 and DBP <90) before being enrolled in the study.
- Is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and/or for up to 180 days after the last dose of study treatment.
- Presence of hepatitis B surface antigen or a positive hepatitis C virus (HCV) antibody test result at Screening or within 3 months prior to first dose of study treatment. Patients with presence of hepatitis B core antibody should also be excluded.
- NOTE: Patients with chronic hepatitis B virus (HBV) infection, who meet the criteria for anti-HBV therapy may be eligible if the participant is on a suppressive antiviral therapy prior to initiation of cancer therapy.
- NOTE: Patients with positive HCV antibody due to prior resolved disease can be enrolled only if a confirmatory negative HCV RNA PCR is obtained. Also, patients with a history of HCV infection may be eligible if they have both: completed curative therapy, have an HCV viral load <quantifiable limit.
- Known history of MDS or AML
- Are immunocompromised. Patients with splenectomy are allowed. Patients with known human immunodeficiency virus (HIV) are allowed if they meet the following criteria:
- Cluster of differentiation 4 ≥350/µL and viral load <400 copies/mL
- No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months prior to enrollment.
- No history of HIV-associated malignancy for the past 5 years. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV [NIH, 2021] started >4 weeks prior to study enrollment.
- Prior immunotherapy toxicities (until resolution to Grade 1 or better)
About this study
Official title: Phase II Study of Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers: A Proof of Concept Study
The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. This study will examine the combination of niraparib and dostarlimab for a synergistic antitumor effect for patients with MSI-H CRC.
Read the detailed description
In this single-arm phase II study, the clinical effectiveness of niraparib in combination with dostarlimab will be investigated for patients with MSI-H colorectal cancer who had disease progression on anti-PD1-based therapy. This study aims to leverage MRE11 deficiency and other HR pathway alterations by using Niraparib and also aims to create potential synergetic effect between dostarlimab with niraparib combination to induce clinically meaningful antitumor benefit. Patients with advanced stage MSI-H CRC who progressed on first line anti-PD1 +/- anti-CTLA4 based therapy will be eligible for this study.
- Conditions
- MMR-D/MSI-H Colorectal Cancers
- Being tested
- Niraparib, Dostarlimab
- Keywords
- PARP inhibitor, MRE11 deficiency, Immune checkpoint inhibitor, Homologous recombination defect, HRD, MSI-H/MMR-D Colorectal cancer, Niraparib, Dostarlimab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NiraparibDrug
Also called Zejula
An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
DostarlimabDrug
Also called Jemperli
An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
| Study group | Role | What they receive |
|---|---|---|
| Niraparib + Dostarlimab | Experimental | Niraparib: 300/200 mg daily (weight-based dosing*)
Dostarlimab: 500 mg Q3 weeks
*Weight-based dosing: Patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/mcL, the niraparib dose is determined to be 300 mg taken orally once daily continuously in combination with dostarlimab 500 mg every 3 weeks.
Patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the niraparib dosage will be 200 mg taken orally, once daily continuously in combination with dostarlimab 500 mg every 3 weeks (Q3W) Receives: Drug: Niraparib; Drug: Dostarlimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective response rate (ORR)
Percentage of evaluable patients that experience an objective response (Complete Response (CR) or Partial Response (PR)), per RECISIT v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm. PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Measured: Up to 12 months
Secondary outcomes (4)
Adverse Events Related to Treatment
Rate of Adverse Events (AEs) related to the niraparib and dostarlimab combination per CTCAE v5.0
Measured: Up to 12 months
Progression-free Survival (PFS)
Median time from first response to treatment until documented disease progression by RECIST v1.1 or death due to any cause. Per RECISIT v1.1, Progressive Disease: ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.
Measured: Up to 36 months
Duration of Response (DoR)
Time from first documented response to disease progression by RECIST v1.1 or death in patients who achieve complete or partial response.
Measured: Up to 36 months
Overall Survival (OS)
Time from assignment to treatment arm until death due to any cause
Measured: Up to 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2024
- Study start31 Jan 2025 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2028 (estimated)
Why it stopped: Per drug sponsor request.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MMR-D/MSI-H Colorectal CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ibrahim Halil Sahin
- Sponsor type
- University, hospital or other
- Collaborators
- GlaxoSmithKline
- Responsible party
- Sponsor-investigator, Ibrahim Halil Sahin, University of Pittsburgh
- Investigators
- Ibrahim H Sahin, MD, Principal investigator, UPMC Hillman Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06365970
- Sponsor's protocol ID
- HCC 23-056
- Status last verified
- Jan 2025
- First submitted
- 29 Mar 2024
- Last updated
- 3 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase II Study of Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers: A Proof of Concept Study
- ClinicalTrials.gov ID
- NCT06365970
- Acronym / sponsor ID
- HCC 23-056
- Conditions
- MMR-D/MSI-H Colorectal Cancers
- Keywords
- PARP inhibitor, MRE11 deficiency, Immune checkpoint inhibitor, Homologous recombination defect, HRD, MSI-H/MMR-D Colorectal cancer, Niraparib, Dostarlimab
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Per drug sponsor request.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Ibrahim Halil SahinUniversity, hospital or other
- Collaborators
- GlaxoSmithKline
- Study start
- 31 Jan 2025 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 15 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. This study will examine the combination of niraparib and dostarlimab for a synergistic antitumor effect for patients with MSI-H CRC.
Detailed description
In this single-arm phase II study, the clinical effectiveness of niraparib in combination with dostarlimab will be investigated for patients with MSI-H colorectal cancer who had disease progression on anti-PD1-based therapy. This study aims to leverage MRE11 deficiency and other HR pathway alterations by using Niraparib and also aims to create potential synergetic effect between dostarlimab with niraparib combination to induce clinically meaningful antitumor benefit. Patients with advanced stage MSI-H CRC who progressed on first line anti-PD1 +/- anti-CTLA4 based therapy will be eligible for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Niraparib + Dostarlimab | Experimental | Drug: Niraparib, Drug: DostarlimabNiraparib: 300/200 mg daily (weight-based dosing*) Dostarlimab: 500 mg Q3 weeks *Weight-based dosing: Patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/mcL, the niraparib dose is determined to be 300 mg taken orally once daily continuously in combination with dostarlimab 500 mg every 3 weeks. Patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the niraparib dosage will be 200 mg taken orally, once daily continuously in combination with dostarlimab 500 mg every 3 weeks (Q3W) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Histologically confirmed mismatch repair deficient or microsatellite instability high advanced stage colorectal cancer
- Measurable disease per RECIST v1.1
- ECOG 0 to 2
- Age ≥ 18 years
- Able to swallow oral medication (tablets).
Key exclusion criteria (36 listed)
- More than 2 lines of systemic therapy (excluding adjuvant therapy)
- Prior oxaliplatin based chemotherapy for metastatic disease. This excludes adjuvant oxaliplatin. Patients who received oxaliplatin based chemotherapy for metastatic disease before determination of MMR-D/MSI-H status (due to test turn-around time) can be enrolled if they received 4 or less cycle of oxaliplatin treatment (each cycle is one dose).
- More than 1 line of anti-PD1 based therapy.
- History of severe hypersensitivity to anti-PD1 monoclonal antibodies
- Prior PARPi
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NiraparibAlso: ZejulaAn anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor. | Drug | Niraparib + Dostarlimab |
| DostarlimabAlso: JemperliAn anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody. | Drug | Niraparib + Dostarlimab |
Primary outcome
Objective response rate (ORR)
Time frame: Up to 12 months
Percentage of evaluable patients that experience an objective response (Complete Response (CR) or Partial Response (PR)), per RECISIT v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm. PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
4 secondary outcomes
Adverse Events Related to Treatment
Time frame: Up to 12 months
Progression-free Survival (PFS)
Time frame: Up to 36 months
Duration of Response (DoR)
Time frame: Up to 36 months
Overall Survival (OS)
Time frame: Up to 36 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for MMR-D/MSI-H Colorectal Cancers
Active, not recruitingPhase 2
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ibrahim H Sahin, MD principal investigator
UPMC Hillman Cancer Center
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Niraparib and Dostarlimab in people with MMR-D/MSI-H Colorectal Cancers, run by Ibrahim Halil Sahin.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 3 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective response rate (ORR) (time frame: Up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2025.